Licensing Terms and Agreements in Pharma, Biotech and Diagnostics, New Report Launched

The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.

Chapter 4 provides a review of the leading licensing deals since 2010. Deals are listed by headline value, signed by bigpharma, most active big pharma, signed by big biotech, most active big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2010, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

                                      

Chapters 6 and 7 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

                   

Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2010 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

          

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2010.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing dealmaking, enabling thorough learning, education and due diligence prior and during the licensing dealmaking process.

Report scope

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.     

Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:

• Trends in licensing dealmaking in the biopharma industry since 2010
• Analysis of licensing deal structure
• Case studies of real-life licensing deals
• Comprehensive listing of licensing deals since 2010
• Access to licensing contract documents
• Key financial bnchmarks for headline, upfront, milestone and royalty rates
• The leading licensing deals by value since 2010
• Most active licensing dealmakers since 2010
• The leading licensing partnering resources

In Licensing Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

Benefits

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:

• In-depth understanding of licensing partnering deal trends since 2010
• Insight into the terms included in a licensing agreement, together with real world clause examples
• Identify leading licensing deals by value since 2010
• Identify the most active licensing dealmakers since 2010
• Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
• Full listing of  licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
• Comprehensive access to over 4,000 licensing deals entered into by the world’s biopharma companies, together with contract documents if available
• Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 1028 pages and 50 Figures “Licensing Terms and Agreements in Pharma, Biotech and Diagnostics” report Covering Executive Summary, Introduction, Trends in licensing dealmaking, Overview of licensing deal structure, Leading licensing deals, Licensing deal term benchmarks, Big pharma licensing deals, Big biotech licensing deals, Licensing contract directory 2010-2014, Appendix.

Know more about this report at – http://mrr.cm/45z

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare